A PHASE III RANDOMIZED, INTERNATIONAL, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL TO STUDY THE TOLERABILITY AND IMMUNOGENICITY OF V503, A MULTIVALENT HUMAN PAPILLOMAVIRUS (HPV) L1 VIRUS-LIKE PARTICLE (VLP) VACCINE, GIVEN TO FEMALES 12-26 YEARS OF AGE WHO HAVE PREVIOUSLY RECEIVED GARDASIL

Registry ID

006-02

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2014-07-15

Last update

2014-04-24

Conditions

• HUMAN PAPILLOMA VIRUS (HPV)

Related clinical trials

• MOLECULAR RESIDUAL DISEASE INTERCEPTION IN LOCOREGIONALLY-ADVANCED HIGH RISK HPV+ AND HPV- HNSCC (MERIDIAN)
• A PHASE III CLINICAL TRIAL TO STUDY THE TOLERABILITY AND IMMUNOGENICITY OF A 2-DOSE REGIMEN OF V503, A MULTIVALENT HUMAN PAPILLOMAVIRUS (HPV) L1 VIRUS-LIKE PARTICLE (VLP) VACCINE, ADMINISTERED IN PREADOLESCENTS AND ADOLESCENTS (9 TO 14 YEAR OLDS) WITH A COMPARISON TO YOUNG WOMEN (16 TO 24 YEAR OLDS)

View on source registry